Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphocholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.40 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.40 |
| ▸ | CHRNA7 known ✓ | P36544 | 3/20 | 0.40 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.40 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.38 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.38 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.35 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.35 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.35 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphocholine SCHEMBL27766488 | 0.98 | CHRM5 (0.41) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL28014826 | 0.88 | SMN1; SMN2 (0.52) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL1802772 | 0.86 | CHRM5 (0.42) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL8773456 | 0.86 | SMN1; SMN2 (0.42) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL19386099 | 0.85 | CHRM5 (0.44) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL1085846 | 0.84 | CHRM5 (0.47) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL27757850 | 0.84 | LPAR3 (0.45) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL18148995 | 0.83 | SMN1; SMN2 (0.39) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Methacrylic Acid SCHEMBL28639506 | 0.83 | SMN1; SMN2 (0.42) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| Phosphocholine SCHEMBL23466865 | 0.82 | LPAR3 (0.43) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260072020-A1 | PRINTABLE MOLECULE-SELECTIVE CORE-SHELL NANOPARTICLES FOR WEARABLE AND IMPLANTABLE SENSING | CALIFORNIA INST OF TECHN (US) | 2026-03-12 | — | — | US | claimed |
| US-20250188521-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. | 2025-06-12 | — | — | US | claimed |
| CN-119529204-A | Triblock expansion viscosity-increasing carbon dioxide channeling profile control agent and preparation method thereof | 中国石油大学(华东) | 2025-02-28 | — | — | CN | claimed |
| US-12220550-B2 | Transdermal delivery device, methods of using and making the same | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-02-11 | — | — | US | claimed |
| US-20240167087-A1 | MULTI-DIMENSIONAL POLYMER SCAFFOLDS FOR NUCLEIC ACID ANALYSES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-23 | — | — | US | claimed |
| US-20240167089-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-23 | — | — | US | claimed |
| EP-4371653-A1 | FABRICATION OF FILTRATION MEMBRANES | Trustees of Tufts College (US) | 2024-05-22 | — | — | EP | claimed |
| CN-114957721-B | Zwitterionic hydrogel and preparation method and application thereof | 四川大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117757127-A | Preparation method of polyethylene material with biocompatibility and application of polyethylene material in medical field | 华东理工大学 | 2024-03-26 | — | — | CN | claimed |
| US-11884977-B2 | Nanoarrays and methods of use thereof | Singular Genomics Systems, Inc. (US) | 2024-01-30 | — | — | US | claimed |
| US-20180001278-A1 | ZWITTERIONIC COPOLYMERS FOR FOULING RESISTANT FILTRATION MEMBRANES | TRUSTEES OF TUFTS COLLEGE | 2018-01-04 | — | — | US | claimed |
| US-9750852-B2 | Modification of bioabsorbable stent to reduce thrombogenecity | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-09-05 | — | — | US | claimed |
| US-20160375143-A1 | MIKTO-ARM BRANCHED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-29 | — | — | US | claimed |
| US-20160303523-A1 | ZWITTERION-CONTAINING MEMBRANES | TUFTS UNIVERSITY (US) | 2016-10-20 | — | — | US | claimed |
| US-20160296676-A1 | MODIFICATION OF BIOABSORBABLE STENT TO REDUCE THROMBOGENECITY | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2016-10-13 | — | — | US | claimed |
| EP-3074440-A1 | MIKTO-ARM BRANCHED POLYMERS | Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) (AU) | 2016-10-05 | — | — | EP | claimed |
| WO-2016109621-A1 | ZWITTERIONIC COPOLYMERS FOR FOULING RESISTANT FILTRATION MEMBRANES | TUFTS UNIVERSITY (US) | 2016-07-07 | — | — | WO | claimed |
| WO-2015077831-A1 | MIKTO-ARM BRANCHED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-06-04 | — | — | WO | claimed |
| WO-2014190398-A1 | INHIBITION OF AMYLOID FIBRIL FORMATION | THE UNIVERSITY OF MELBOURNE (AU) | 2014-12-04 | — | — | WO | claimed |
| US-20120290075-A1 | MODIFICATION OF BIOABSORBABLE STENT TO REDUCE THROMBOGENECITY | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2012-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375143-A1 | MIKTO-ARM BRANCHED POLYMERS | MACO1, PCNA, IPO7 | CHRM5 4089/4885CHRM1 3738/4885CHRM3 3148/4885 |
| US-20260072020-A1 | PRINTABLE MOLECULE-SELECTIVE CORE-SHELL NANOPARTICLES FOR WEARABLE AND IMPLANTABLE SENSING | MIF, HMOX2, HMOX1 | CHRM5 2389/4885CHRM1 2135/4885CHRM3 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.